Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00319852 | Immunogenicity and Safety of Tetraxim Versus Local DTP + IPV | PHASE3 | COMPLETED | 442 | — | — | Apr 1, 2006 | Jul 1, 2008 | Apr 16, 2012 | 1 | South Korea |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| DTaP-IPV combined vaccine | BIOLOGICAL | 0.5 mL, IM |
| DTaP vaccine | BIOLOGICAL | 0.5 mL, IM |
Inclusion Criteria: * Aged 56 to 70 days inclusive on the day of inclusion * Born at full term pregnancy (\>37 weeks) with a birth weight ≥ 2.5 kg * Informed consent form signed by the parent(s) or other legal representative * Able to attend all scheduled visits and to comply with all trial procedu...